Coreg CR and ACE inhibitor: Development discontinued

GSK terminated development of a fixed-dose combination of Coreg CR and an undisclosed angiotensin-converting enzyme (ACE) inhibitor, which was in Phase III testing to treat hypertension. Coreg CR, whi...